Biomarkers in the diagnosis and study of psychogenic nonepileptic seizures: A systematic review  by Sundararajan, T. et al.
Seizure 35 (2016) 11–22Review
Biomarkers in the diagnosis and study of psychogenic nonepileptic
seizures: A systematic review
T. Sundararajan a, G.E. Tesar a,b, X.F. Jimenez a,*
aCleveland Clinic Department of Psychiatry and Psychology, United States
bCleveland Clinic Epilepsy Center, United States
A R T I C L E I N F O
Article history:
Received 30 October 2015
Received in revised form 22 December 2015
Accepted 24 December 2015
Keywords:
Psychogenic nonepileptic seizures
Biomarker
Epilepsy
Conversion disorder
Pseudoseizures
A B S T R A C T
Objective: Video electroencephalography (vEEG) is the gold-standard method for diagnosing psycho-
genic nonepileptic seizures (PNES), but such assessment is expensive, unavailable in many centers,
requires prolonged hospitalization, and many times is unable to capture an actual seizure episode. This
paper systematically reviews other non-vEEG candidate biomarkers that may facilitate both diagnosis
and study of PNES as differentiated from epileptic seizures (ES).
Methods: PubMed database was searched to identify articles between 1980 and 2015 (inclusion: adult
PNES population with or without controls, English language; exclusion: review articles, meta-analyses,
single case reports).
Results: A total of 49 studies were examined, including neuroimaging, autonomic nervous system,
prolactin, other (non-prolactin) hormonal, enzyme, and miscellaneous marker studies. Functional MRI
studies have shown PNES is hyperlinked with dissociation and emotional dysregulation centers in the
brain, although conﬂicting ﬁndings are seen across studies and none used psychiatric comparators. Heart
rate variability suggests increased vagal tone in PNES when compared to ES. Prolactin is elevated in ES
but not PNES, although shows low diagnostic sensitivity. Postictal cortisol and creatine kinase are
nonspeciﬁc. Other miscellaneous biomarkers (neuron speciﬁc enolase, brain derived neurotropic factor,
ghrelin, leptin, leukocytosis) showed no conclusive evidence of utility. Many studies are limited by lack
of psychiatric comparators, size, and other methodological issues.
Conclusion: No single biomarker successfully differentiates PNES from ES; in fact, PNES is only diagnosed
via the negation of ES. Clinical assessment and rigorous investigation of psychosocial variables speciﬁc to
PNES remain critical, and subtyping of PNES is warranted. Future investigational and clinical imperatives
are discussed.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Psychogenic nonepileptic seizures (PNES) are a form of
conversion disorder deﬁned as paroxysmal episodes resembling
epileptic seizures (ES) while lacking electroencephalographic
(EEG) correlation [1,2]. Changes in diagnostic methods for PNES
have evolved over the years, though video electroencephalography
(vEEG) is currently considered the best diagnostic option in
determining ES from PNES [2]. Nonetheless, this methodology is
costly, available in selected clinical environments and of value only* Corresponding author at: Neurological Institute, Cleveland Clinic Foundation,
9500 Euclid Ave., P57, Cleveland, OH 44195, United States. Tel.: +1 216 407 4994;
fax: +1 216 445 7032.
E-mail address: jimenex2@ccf.org (X.F. Jimenez).
http://dx.doi.org/10.1016/j.seizure.2015.12.011
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reif a typical episode occurs during monitoring. Furthermore, while
vEEG assessment ﬁrmly establishes the presence or absence of
epileptic discharges, PNES can only be inferred and not established.
Diverse theories have been proposed to describe core psychopath-
ological deﬁcits, traits, or mechanisms driving PNES [3–5], but no
pathognomonic biological, psychological, or social marker has
been identiﬁed.
Given the aforementioned limitations in the use of vEEG for
diagnosing PNES, it is prudent to continue to understand the value
of other diagnostic modalities. Much emphasis has recently been
applied to presumed neurobiological underpinnings of PNES [6],
with various lines of investigation seeking candidate biomarkers
elucidating pathophysiology, in turn informing potential therapies
[7]. Such a clear marker indicating the presence (or absence) of
PNES is always in demand amongst clinicians. In order to assess the
relative values of potential biomarkers, we conducted a systematicserved.
T. Sundararajan et al. / Seizure 35 (2016) 11–2212review of the diagnostic and investigational utility of all candidate
PNES biomarkers to date. We felt compelled to review this from
both clinical and investigational angles as an update for the ﬁeld in
order to begin to prioritize diagnostic, treatment, and research
imperatives relevant to PNES. Many studies are emerging focusing
on the neuroimaging or other biological aspects of PNES; while we
support this and feel there is a need for such investigations, we also
aim to demonstrate a lack of attention to non-biological markers,
such as psychosocial measures. PNES is a complex condition
warranting a complex approach; we hope to illustrate with this
systematic review that biological reductionism may not be useful
in our investigational or (especially) clinical endeavors with PNES.
We hypothesized that this review would reveal a paucity of
evidence supporting any one biomarker in the diagnosis or study of
PNES and set out to test this with a systematic examination of
existing literature.
2. Methods
We conducted an extensive literature search utilizing PubMed
and the following terms: ‘‘psychogenic non epileptic seizures,’’
‘‘pseudoseizure,’’ ‘‘non-epileptic attacks,’’ ‘‘functional epilepsy,’’
‘‘hysterical seizure,’’ ‘‘psychogenic seizure,’’ ‘‘seizures,’’ and ‘‘epi-
lepsy.’’ These terms were used in various combinations with a
variety of terms used routinely in medicine as biomarkers ofRecords  idenﬁe 
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trophins,’’ ‘‘neurotransmitter,’’ ‘‘ammonia,’’ ‘‘oxygen,’’ ‘‘carbon
dioxide,’’ ‘‘metabolism,’’ ‘‘heart rate,’’ and ‘‘blood pressure.’’ Finally,
we also included terms capturing methodologies of assessment
and/or sampling approaches: ‘‘galvanic skin response,’’ ‘‘skin,’’
‘‘pupil,’’ ‘‘autonomic nervous system,’’ ‘‘serum,’’ ‘‘cerebrospinal
ﬂuid,’’ ‘‘computed tomography (CT),’’ ‘‘magnetic resonance imag-
ing (MRI)’’, ‘‘functional MRI (fMRI),’’ and ‘‘neuroimaging.’’ Studies
published between 1980 and 2015 were screened initially, and
additional articles were identiﬁed via references. Studies included
had both ES and PNES patients with or without healthy controls
(HC). Select case reports with pertinent ﬁndings were also
included. Exclusion criteria included other forms of conversion
disorder (including functional movement disorders), review
articles, meta-analyses, and articles in languages other than
English. We did not include electrographic studies including
EEG/vEEG or single photon emission CT (SPECT) because these are
neurophysiological tests currently considered to be the most
robust or best available approaches to assessing ES versus PNES;
vEEG speciﬁcally is considered the gold-standard of seizure
diagnosis while SPECT is less commonly-utilized. Ultimately, a
total of 49 articles were included for systematic review. A modiﬁed
PRISMA ﬂowchart for our systematic review methodology is given
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experts (explained and cited in discussion section).
3. Results
The ﬁndings of our review are organized under various
headings as follows:Table 1
Neuroimaging studies in PNES.
Ref. Study Imaging n PNES ES HC Stu
[8] Benbadis
et al. (2000)
MRI 4 4 0 0 Cas
[9] Devinsky
et al. (2001)
CT, MRI 201 79 122 0 Ret
[10] Reuber
et al. (2002)
MRI (plus EEG
and neuropsychiatric
evaluation–NPS)
329 329 123 0 Ret
[11] Labate et al.
(2012)
MRI (voxel based
morphometry,
cortical thickness)
60 20 0 40 Cas
[12] Wieshmann
et al. (2002)
CT, MRI 495 18 477 0 Cro
[13] Ristic et al.
(2015)
MRI 74 37 0 37 Cas
[14] Lee t al (2015) Diffusion tensor
imaging
32 16 0 16 Cas
[15] Ding et al.
(2013)
fMRI (structural,
functional & DT)
37 17 0 20 Cas
[16] Ding et al.
(2014)
fMRI 37 17 0 20 Cas
[17] Li et al. (2014) fMRI (insular
subregions)
37 17 0 20 Cas
[18] Van der Kruijs
et al. (2011)
fMRI 23 11 0 12 Cas
[19] Van der Kruijs
et al. (2014)
fMRI 48 21 0 27 Cas
[20] Arthuis
et al. (2014)
FDG-PET 32 16 0 16 Cas
[21] Hernando
et al. (2015)
Diffusion tensor
imaging
16 8 0 8 Cas
PNES, psychogenic nonepileptic seizure; ES, epileptic seizure; HC, healthy control; CT, co
sclerosis; NPS, neuropsychiatric scale; FC, functional connectivity; fMRI, functional magn
positron emission tomography; UF, uncinate fasciculus; ACC, anterior cingulate cortex; OFC3.1. Neuroimaging markers
A number of structural neuroimaging approaches have been
used to study abnormalities associated with PNES (Table 1).
Structural central nervous system (CNS) abnormalities on CT
and MRI have been demonstrated to varying degrees in patients
with PNES when compared to ES, although studies have beendy type Results/ﬁndings Strengths/limitations/
comments
e series All abnormal MRI (mesial
temporal sclerosis), while PNES
on EEG; MTS not speciﬁc to ES
Very small sample size, no HC
group
rospective 85% PNES 1 ﬁnding, unclear
signiﬁcance (+ RT-sided
laterality)
No HC group
rospective PNES 22% 1 ﬁnding (EEG 9%,
MRI 10%, NPS 10%) PNES + ES:
92% 1 ﬁndings (EEG 71%, MRI
60%, NPS 53%) MRI
abnormalities: PNES + ES > PNES
(p < 0.0001)
Retrospective, missing MRI/
NPS testing in 55% of PNES
group, no HC group
e control PNES gray matter thinning in RT
premotor region, bilateral
cerebellum > HC (p < 0.05);
No ES group; no psychiatric
comparator
ss sectional 0% PNES with ﬁndings; 51% ES
1 ﬁnding
No HC group
e control PNES cortical thickness LT insula,
b/l OFC > ES (p < 0.05); PNES b/l
insular sulcal depth > HC
(p < 0.001); PNES cortical surface
area = HC
No ES group; no psychiatric
comparator
e control PNES white matter connectivity
corona radiata, LT temporal
gyrus, LT internal/external
capsules, LT UF > HC (p < 0.05)
Sample size, no ES group, no
psychiatric comparator
e control PNES decreased FC/structural
connectivity (decreased
coupling); ‘‘lattice-like’’
organization > HC (p < 0.001)
Sample size, no ES group, no
psychiatric comparator
e control PNES increased FC between
lateral middle frontal gyrus, ACC,
SMA, b/l median cingulate,
insula, occipital cortex > HC
(p < 0.05)
Small sample size, possibility
of head motion artifact, no
psychiatric comparator
e control PNES increased FC between
insular sub regions and
sensorimotor network, ingual
gyrus, superior parietal gyrus,
putamen > HC (p < 0.05).
Same patients as in Ding
et al., 2013/2014 studies;
small sample size; no
psychiatric comparator
e control PNES increased FC in insula,
inferior frontal gyrus, parietal
sulcus > HC (p < 0.05); higher
dissociation > HC (p < 0.05)
Findings confounded by
dissociation; no psychiatric
comparator
e control PNES increased coactivation of
cingulate/insular network;
cingulate superior parietal lobe,
pre/post central gyri, SMA
network; and precuneus
network > HC; higher
dissociation > HC (p < 0.05)
Findings confounded by
dissociation; no psychiatric
comparator
e control PNES hypometabolism RT
inferior parietal/central and b/l
ACC > HC (p < 0.001).
Retrospective, small sample,
PTSD/anxiety not controlled
for; no psychiatric
comparator
e control PNES greater UF streamlines in
right hemisphere > HC
(p < 0.03).
Sample size, due to technical
limitations were not able to
include all connecting
streamlines belonging to UF,
minor pathways not
included, female
preponderance
mputational tomography; MRI, magnetic resonance imaging; MTS, medial temporal
etic resonance imaging; DT, diffusion tractography; FDG-PET, ﬂuorodeoxyglucose-
, orbitofrontal cortex; SMA, supplementary motor area; RT, right; LT, left; b/l, bilateral.
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et al. [9] found a preponderance of right hemisphere structural
abnormalities in a cohort of 79 PNES patients when compared to
the ES group, although this is of unclear signiﬁcance. In a group of
20 PNES patients, brain MRI revealed abnormal gray matter
thinning in the right premotor region which positively correlated
with incidence of depression [11]. Other studies, however, have
found no increased incidence of structural brain abnormalities in
PNES as compared to ES [12]. Ristic et al. [13] showed that patients
with PNES possessed increased cortical thickness in the left insula
and bilateral medial orbitofrontal cortex, as well as increased
sulcal depth in bilateral insula and right cingulate when compared
to HC, but no differences in terms of cortical surface area or cortical
curvature. Similarly, Lee et al. [14] revealed increased white matter
connectivity (as measured by fractional anisotropy) in the left
corona radiata, internal/external capsules, temporal gyrus, and
uncinate fasciculus amongst PNES patients when compared to HC.
Although these indicate some potential differences between
patients with PNES and HC in terms of brain morphology, various
limitations are to be noted (see next paragraph and Section 4).
At least seven studies have used fMRI techniques to investigate
PNES patients. In two studies sampling the same subjects (n = 17),
Ding et al. have shown increased functional connectivity between
various cortical areas as well as a ‘‘lattice-like’’ organization in
functional and structural connectivity networks in PNES subjects
when compared to HC [15,16]. Li et al., utilizing once again the
same cohort as Ding et al., have demonstrated hyperlinked
functional connectivity in insular subregions in PNES [17]. van
der Kruijs et al. have shown increased coactivation of cingulate and
insular cortices in PNES when compared to HC, and identiﬁed a
correlation between such coactivation and both dissociation and
emotional dysregulation [18,19]. Positron emission tomography
(PET) has revealed a pattern more akin to anxiety or posttraumatic
stress disorders (PTSD), characterized by hypo-metabolism in theTable 2
Autonomic nervous system studies in PNES.
Ref. Study Bio-
marker
N
(events)
PNES
(events)
ES
(events)
HC Stud
type
[24] Opherk et al.
(2002)
HR 105 38 67 0 Cross
[25] Oliveira et al.
(2007)
HR 59 20 39 0 Retro
[26] Oliveira et al.
(2009)
HR 143 50 93 0 Retro
[27] Reinsberger
et al. (2012)
HR 88 42 46 0 Retro
[28] Mungen
et al. (2010)
SSR 75 25 30 20 Cross
[29] Ponnusamy
et al. (2011)
HRV 129 52 42 35 Cross
[30] Ponnusamy
et al. (2012)
HRV 50 24 26 0 Retro
[31] Reinsberger
et al. (2015)
EDA 20 9 11 0 Case
(pilo
PNES, psychogenic non epileptic seizure; ES, epileptic seizure: HC, healthy control; GTC
seizure; IC, interictal; PI, postictal; HR, heart rate; BPM, beats per minute; HRV, heart ra
sympathetic skin response; SDNN, standard deviation of NN interval; CSI, cardio sympath
activity; EDR, EDA responses.right inferior parietal and bilateral anterior cingulate cortices [20].
Hernando et al. [21] utilized diffusion tensor tractography to
observe dense right hemisphere uncinate fasciculus involvement
in PNES as compared to HC. Though these imaging studies are not
meant for differentiating PNES from ES, they may contribute
insights into the neural basis of PNES. However, they are limited by
heterogeneous methodologies, small sample sizes, a lack of ES
comparison groups, and a lack of psychiatric comorbidity control.
These limitations will be discussed further in a later section.
3.2. Autonomic nervous system
Table 2 summarizes studies examining autonomic nervous
system (ANS) changes in PNES as compared to ES. Autonomic
dysfunction has long been studied in epilepsy, as passage of
epileptic discharges through subcortical limbic structures such as
the amygdala, hippocampus, hypothalamus, and insula results in
centrally-mediated sympathetic and parasympathetic nervous
system changes [22]. Cortical areas such as the insular, anterior
cingulate, posterior-orbitofrontal and pre-frontal cortices are
similarly implicated in centrally-mediated changes of the ANS
[23].
Studies have compared heart rate (HR) and heart rate variability
(HRV) responses to seizure events in ES and PNES groups. One
study showed that maximal ictal HR above 130 beats per minute
(BPM) differentiated ES from PNES with a reported sensitivity of
83%, speciﬁcity of 96%, and positive predictive value of 97% [24].
Oliveira et al. also reported ictal tachycardia in 100% of ES (complex
partial) patients as compared to zero PNES subjects [25]; the
authors replicated this in another cohort, ﬁnding ictal and postictal
HR elevations in ES (complex partial seizures; CPS) but not PNES
groups [26]. Reinsberger et al. found both pre ictal and postictal HR
(but not ictal HR) was signiﬁcantly higher in ES (complex partial)
than PNES [27].y Results/ﬁndings Strengths/limitations/
comments
 sectional ES ictal onset HR > PNES
(p < 0.05) ES ictal HR > PNES
(p < 0.001) ES PI HR > PNES
(p < 0.001)
No age/gender demographics
noted
-spective CPS ictal/PI HR rise > SPS, PNES
(no rise; p > 0.05)
Retrospective
-spective ES mild/mod/severe ictal
HR > PNES mild/mod ictal HR
(p < 0.05) (only PNES severe ictal
HR increased, but return to
baseline while no return in ES)
Retrospective
-spective ES preictal and PI HR > PNES
(p < 0.006 and p < 0.015) ES ictal
HR = PNES (p < 0.493)
Retrospective; age
distribution not mentioned
- sectional ES UE SSR > PNES (p < 0.05) Not all patients had ictal
VEEG
-sectional ES SDNN < PNES (p < 0.01) PNES/
ES HRV < HC (p < 0.03) PNES
CSI > HC (p < 0.003)
Various potential
confounders (comorbid
conditions, AED effects, pre-/
post-ictal effects)
-spective ES CSI > PNES (p < 0.001). ES:
High ictal HRV changes = high
sympathetic/reduced vagal tone
Retrospective study design
 control
t study)
ES EDR > PNES (p = 0.0074) Pilot study; comorbid
psychiatric conditions in
various subjects (PTSD, GAD,
etc.)
S, generalized tonic clonic seizure; CPS, complex partial seizure; SPS, simple partial
te variability; VEEG, video EEG; AED, anti-epileptic drug; UE, upper extremity; SSR,
etic index; FFT technique, fast Fourier transformation technique; EDA, electrodermal
T. Sundararajan et al. / Seizure 35 (2016) 11–22 15Other measures of ANS function have been conducted in ES and
PNES cohorts. Mungen et al. assessed sympathetic (galvanic) skin
response, ﬁnding signiﬁcantly-prolonged response latency in
upper extremities of ES both postictally and interictally when
compared to PNES [28]. Ponnusamy et al. used time and frequency
domains of HRV as measures of vagal tone, correctly identifying
86% of HC subjects from PNES patients using various HRV
parameters, though only one parameter (the standard deviation
of NN intervals) showed statistically-signiﬁcant difference be-
tween ES and only a subgroup of PNES patients [29]. A second
investigation by Ponnusamy et al. examined resting and ictal ANS
changes and found that ES (CPS) groups had higher sympathetic
tone than PNES cohorts and showed that 88% of ES and 73% of PNES
diagnoses were identiﬁed correctly using their HRV parameters
[30]. These studies in combination suggest that HRV is a superior
ANS measure than HR alone in differentiating ES from PNES.
As an additional measure of ANS function, one recent pilot case
control comparison of 9 ES and 11 PNES subjects suggested
increased electrodermal responses (EDR) in ES when compared to
PNES, although the study was limited by sample size and various
uncontrolled psychiatric comorbidities [31].
3.3. Hormones
Various hormones have been suggested as biomarker candi-
dates in the differentiation between ES and PNES. Tables 3 and 4
summarize studies involving prolactin and other hormones,
respectively.
3.4. Prolactin
Prolactin (PRL), a polypeptide secreted by lactotrophic cells of
the anterior pituitary gland, was ﬁrst isolated in 1970s [32].
Ohman et al. [33] ﬁrst reported serum PRL elevations following ES
in the context of electroconvulsive therapy (ECT), and elevations
following spontaneous ES were later described [34]. In ES,
propagation of epileptic discharges from mesial temporal struc-
tures to the hypothalamus likely results in postictal PRL releases
[35].
Multiple studies have revealed elevated PRL levels in ES groups
(but not PNES groups) as early as 10–20 min postictally, remaining
elevated for up to 2 h thereafter [36–46]. ES patient groups had
signiﬁcantly elevated PRL levels than PNES. With capillary PRL
assays, one study found 69% sensitivity (SS) and 93% speciﬁcity (SP)
in differentiating ES from PNES [47] while another group reported
100% positive predictive value (PPV) in the diagnosis ES [48].
Two of the selected studies, however, failed to support use of
PRL as a biomarker. One study found elevated postictal PRL in up to
20% of the PNES cohort [49], while a second group found no
statistically-signiﬁcant difference in postictal PRL between ES and
PNES subjects [50].
3.5. Other hormones
Cortisol, a polypeptide hormone integral to stress processing, is
released from the adrenal cortex in response to adrenocorticotro-
phic hormone (ACTH), itself released in response to hypothalamic
secretion of corticotrophin releasing hormone (CRH) [51]. Cortisol
is known to act on glucocorticoid receptors of the hypothalamus,
pituitary, hippocampus, and amygdala to maintain complex
homeostatic needs [52].
Studies on postictal cortisol levels have shown mixed results
[37,39,42,53]. Tunca et al. reported a rise in cortisol levels during
PNES events when compared with basal cortisol levels in HC [54].
Zhang and Liu found a typical pattern of pre-ictal fall and postictal
rise of cortisol in ES but no such changes in PNES [55]. Other studiesby Bakvis et al. have demonstrated PNES patients possess basal
hypercortisolism positively correlated with both traumatic histo-
ries and threat vigilance [56,57].
Regarding other hormone candidates, Rao et al. [39] found
serum elevations in a number of pituitary hormones such as
growth hormone and thyrotropin releasing hormone along with
PRL and cortisol following ES but not PNES. Adrenocorticotropic
hormone (ACTH) is yet another stress-processing hormone whose
level has been observed to be higher in ES but not in PNES
postictally in older studies with small sample sizes [53,58]; despite
this, the previously-mentioned Zhang and Liu study did not
demonstrate this difference [55], calling into question the utility of
ACTH in the differentiation of ES from PNES.
3.6. Enzymes
Table 5 lists studies evaluating enzymes as potential biomark-
ers differentiating ES from PNES.
3.7. Creatine kinase
Creatine kinase (CK) is a muscle-speciﬁc enzyme that catalyzes
the phosphorylation of creatine to form creatine phosphate, a
major energy reserve. Four studies have studied the utility of
serum CK in differentiating ES from PNES, and they suggest some
utility in postictal CK levels, with a sensitivity of 75%, speciﬁcity of
85.5%, positive predictive value of 62.5%, and negative predictive
value of 91.4% [43,59,60,61]. These results should be interpreted
with caution as CK may be elevated in a number of other clinical
situations [62,63].
3.8. Neuron-speciﬁc enolase
Neuron-speciﬁc enolase (NSE) is a dimeric intracytoplasmic
glycolytic enzyme present in neurons and cells of neuroectodermal
origin [64]; it is not physiologically secreted, yet released under
pathological conditions such as neuronal injury with detection in
peripheral circulation as a result of blood–brain barrier disruption
[65,66]. NSE has been evaluated as a biomarker in various
neurological conditions [67–69] as well as major depressive
disorder [70]; it has been found to be elevated in both febrile
seizures [71] and other ES [72–74].
Two studies have compared postictal NSE levels amongst ES
and PNES patients [43,75], each failing to show any postictal
elevation from baseline in PNES cohorts. In addition, this
biomarker is limited by falsely elevated levels in any hemolytic
conditions [76,77].
3.9. Miscellaneous
Additional studies involving other biomarkers including
neuropeptides and cell counts are summarized in Table 5.
3.10. Neuropeptides
Ghrelin and nesfatin-1 have gained importance due to their role
in appetite regulation. Ghrelin exerts anticonvulsant action by
acting on the receptor-growth hormone secretagogue receptor 1a,
in turn increasing gamma-aminobutyric acid (GABA) concentra-
tion in the hypothalamus [78]; nesfatin depolarizes paraventri-
cular and arcuate nuclei neurons [79].
Aydin et al. have reported elevated postictal serum and salivary
nesfatin in ES but not in PNES, whereas they detected lower
postictal serum ghrelin levels in ES when compared to PNES [44].
Unfortunately, no difference was found in the levels of these
biomarkers between PNES and HC groups, calling into question
Table 3
Prolactin studies in PNES.
Ref. Study Bio-
marker
N
(events)
PNES
(events)
ES
(events)
HC Sample timing
(min/h)
Results/ﬁndings Strengths/limitations/
comments
[36] Collins et al. (1983) PRL 36 8 28 0 PI: 5, 15, 30, 60, 90, 120, 180min AUC/CMAX ES>PNES
(p<0.001)
No BL measure
[37] Pritchard et al. (1985) PRL 12 6 6 0 BL; PI: 15, 30, 45, 60min PI PRL ES>PNES [15min
(p<0.02); 30min (p<0.005),
45min (p<0.05), 60min
(p<0.02)]
Small sample; all PNES patients
were male; no control for AED
effects
[38] Laxer et al. (1985) PRL 85 21 64 0 PI: 20min, 24h PI PRL rise ES>PNES (p<0.001);
PI PRL rise SPS>PNES (p<0.1)
Signiﬁcant ﬁndings
[39] Rao et al. (1989) PRL 40 6 6 28 Ictal, PI: 0–2h, q15min PI PRL decrease ES>PNES Small sample size
[40] Wroe et al. (1989) PRL 33 10 23 0 q2h during admission;
PI: 0, 2, 5, 10, 20, 30, 60, 120min
PI PRL ES>PNES/absence SZ Most PRL assessments of all
[41] Bauer et al. (1992) PRL 78 11 47 20 PI: q 20min24h PI PRL ES>PNES Small sample size
[42] Mehta et al. (1994) PRL 97 9 78 10 IC; PI: 10, 20, 30, 60, 120min PI PRL ES>PNES (GTCS: 68.33%,
PS: 11.11%, PNES: 0%)
Small sample size
[43] Willert et al. (2004) PRL 60 12 32 16 Daily sampling, unclear timing PI PRL ES (10min – 24h)>PNES
(92% ES vs 41% PNES)
Unclear sampling methods,
small size
[44] Aydin et al. (2011) PRL 70 16 34 20 PI within 5min; 1, 24, 48h PI PRL ES>PNES/HC (p<0.05) Signiﬁcant ﬁndings; only male
study group
[45] Shah et al. (2001) PRL 340 102 238 0 BL, PI within 40min PI PRL ES>PNES (p<0.01) No mention of age distribution
[46] Anzola (1993) PRL 59 19 40 0 Admission/BL, 1 hr following;
AM day two, AM day three
PI PRL ES>PNES (p<0.005);
PI>60min: no stat. sig.
difference
PNES= ‘‘syncopal attacks’’
(despite excluding cardiac
causes)
[47] Ehsan et al. (1996) PRL (+ cap) 50 14 36 0 PI: 15, 75min PI PRL ES>PNES (SS: 69%, SP:
93%)
No baseline; assessed
venous+capillary PRL
[48] Fisher et al. (1991) PRL (+ cap) 20 4 16 0 PI: within 20min PI Venous PRL ES/
PNES> capillary PRL ES/PNES
(p=0.5) capillary PRL PPV 100%
GS, 71% CPS, 100% PNES (NPV)
Small PNES size; no baseline;
assessed venous+ capillary PRL
[49] Alving (1998) PRL 58 20 38 0 PI 15min; 2h PI PRL rise ES>PNES (p<0.001);
20.4% PNES relative increase>2x
Low SS/SP/PPV in determining ES
vs PNES
[50] Shukla et al. (2004) PRL 36 19 17 0 PI: 15–20min PI PRL ES=PNES (p=0.24) Single PI PRL level; no BL
measure; no stat. sig. difference
SZ, seizure(s); PNES, psychogenic non epileptic seizure; ES, epileptic seizure; HC, healthy control; PRL, prolactin; GTCS, generalized tonic clonic seizures; GS, generalized seizure; CPS, complex partial seizure; PS, partial seizure; PI,
postictal; IC, interictal; AUC, area under curve; CMAX,maximum concentration; TMAX, time taken to attainmaximum level; BL, baseline; VEEG, video EEG; PPV, positive predictive value;min,minute(s); h, hour(s); cap, capillary; SS,
sensitivity; SP, speciﬁcity.
T
.
 Su
n
d
a
ra
ra
ja
n
 et
 a
l.
 /
 Seizu
re
 3
5
 (2
0
1
6
)
 1
1
–
2
2
1
6
Table 4
Hormonal studies in PNES (prolactin excluded).
Ref. Study Biomarker n PNES ES HC Sample timing Results/ﬁndings Limitations/comments
[37] Pritchard (1985) Cortisol 12 6 6 0 Baseline; PI: 15, 30, 45, 60min Baseline ES>PNES; PI cortisol
ES>PNES (p<0.001)
No HC group; small sample size
[39] Rao et al. (1989) Cortisol, TRH,
GH, catecholamine
(NE), melatonin
40 6 6 28 IC/PI: 0–2 hr, every 15min;
24 hr: every 3–4hrs 3
additional samples hourly
PI PRL & TRH ES>PNES
(p>0.05); PI GH ES (and
decrease)>PNES (p<0.02);
Cortisol ES>PNES; Mean NE ES/
PNES<HCl
Small sample size
[42] Mehta et al. (1994) Cortisol 97 9 78 10 PI: 10, 20, 30, 60, 120min; IC PI cortisol PNES>ES (no stat
signiﬁcance)
Small sample (PNES) size
[53] Gallagher et al. (1984) ACTH, cortisol 37 5 23 9 1st: 8–9.30 AM, every 5min
2nd: 2–4PM, every 5min
ACTH ES>PNES (p<0.05);
cortisol mean and rate no
statistical signiﬁcance
No demographics; only AM level
compared between ES/PNES; 11
ES patients post-lobectomy
[54] Tunca et al. (2000) Cortisol 26 18 0 8 IC, circadian (11–12AM,
1–2PM, 4–5PM); day two 8AM
IC/AM/PM cortisol PNES>HC
(p=0.22)
No ES control group
[55] Zhang et al. (2008) ACTH, cortisol 47 11 36 0 8AM (wake), 12AM (sleep) ACTH changes ES=PNES; PM
cortisol PNES slightly>wake
level (p>0.05)
No HC group
[56] Bakvis et al. (2009) Cortisol (saliva, as
correlated to AB
56 19 17 20 40min pre-AB task (angry faces) Correlation PNES vs ES: Z=1.64
(p=0.05); PNES vs HC: Z=1.52
(p=0.064)
No difference in correlations
[57] Bakvis et al. (2010) Cortisol (saliva) 37 18 0 19 Awakening cortisol: 0, 15, 30,
45, 60min; post DST
CAR PNES=HC (p<0.279); post
DST PNES=HC after controlling
for confounders (smoking,
psychotropic medications)
No ES control group
[58] Gallagher (1987) ACTH 10 5 5 0 8–9.30AM, every 5min Mean ACTH ES>PNES (p<0.05) No HC group; small sample size
PNES, psychogenic nonepileptic seizure; ES, epileptic seizure; HC, healthy control; PI, post ictal; IC, interictal; GTCS, generalized tonic clonic seizure; PS, partial seizure; ACTH, adrenocorticostimulating hormone; CAR, cortisol
awakening response; DST, dexamethasone suppression test; SS, statistical signiﬁcance; NE, nor epinephrine; AB, attentional bias.
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Table 5
Miscellaneous (enzyme, cellular) biomarker studies in PNES.
Ref. Study Biomarker n PNES ES HC Sampling time Results/ﬁndings Limitations/comments
[43] Willert et al.
(2004)
NSE, CK 60 12 32 16 Baseline; PI 10, 20,
30 min & 1, 6, 12, 24 h
PI NSE/CK ES > PNES;
(p = 0.017);
Early termination of study
missing delayed CK release
[44] Aydin et al.
(2011)
Nesfatin-1,
ghrelin
70 16 34 20 PI within 5 min,
1, 24, 48 hr
PI nesfatin ES > PNES/HC
(p < 0.05); PI ghrelin
ES < PNES/HC (p < 0.05);
+nesfatin/PNES
Only male study group; unclear
signiﬁcance
[45] Shah et al.
(2001)
WBC count 340a 102a 238a 0 Baseline, PI PI WBC ES > PNES (p < 0.01) Unclear demographics; no HC
group
[59] Wyllie
et al. (1985)
CK 22 6 16 0 Daily random
samples, quantity
PI CK ES > PNES (p = 0.05) Unclear sampling time/
quantity; no HC group; small
sample size
[60] Holtkamp
et al. (2006)
CK 18 8 10 0 PI (within 24 hr) Low CK level in PNES than ES;
PNES 38 U/l vs ES 699 u/
l(p = 0.001) (n = 8 each)
Retrospective study design;
small sample size; no HC group
[61] Petramfar
et al. (2009)
CPK 82 20 20 20
(+ 22 VVS)
PI (within 12–15 hrs) PI CPK ES > PNES/HC
(p < 0.0001).
No baseline level; diagnostic
heterogeneity (vasovagal HC
group)
[75] Rabinowicz
et al. (1996)
NSE 43 10 15 18 Baseline; PI Baseline NSE ES = PNES; PI
CNSE ES = PNES
No signiﬁcant ﬁndings
[84] LaFrance
et al. (2010)
BDNF 44 12 15 17 Unknown sampling
methods
BDNF PNES < HC (p < 0.001);
BDNF ES < HC (p < 0.001);
BDNF PNES = ES (p < 0.868)
Unclear sampling time/
quantity; HC average 20 years
younger than ES/PNES
[87] Cupello
et al. (2008)
Platelet
membrane
serotonin
transport
(SERT)
66 16 27 23 PI, within 4 days Paroxetine binding ES within 4
days < HC/ES past 4 days
(p < 0.01); paroxetine BMAX
ES < HC (p < 0.001) & PNES
(p < 0.01)
Single sample; no baseline
level for controls; ES group
with seizure past 4 days data
taken from previous Cupello
et al. study (2005)
PNES, psychogenic non epileptic seizure; ES, epileptic seizure; HC, healthy control; PI, postictal; NSE, neuron speciﬁc enolase; CK, creatine kinase; CPK, creatine
phosphokinase; VVS, vasovagal syncope; BDNF, brain derived neurotropic factor; WBC, white blood cell; BMAX, density of serotonin uptake sites.
a Events.
T. Sundararajan et al. / Seizure 35 (2016) 11–2218their utility; their use in differentiating ES from PNES remains to be
determined via replication studies.
3.11. Brain derived neurotrophic factor
Brain derived neutrotrophic factor (BDNF) is a neurotrophin
with important effects on neurogenesis and neuronal plasticity
[80], abundantly present in the hippocampus and the entorhinal
cortex [81]. Increased serum BDNF has been demonstrated in
children with epilepsy [82], while lowered amounts were noted in
conversion disorder and major depressive disorder [83]. Only one
study by Lafrance et al. demonstrated lower postictal BDNF in
patients with ES and PNES when compared to HC [84], thereby
lacking speciﬁcity in differentiating seizure types.
3.12. Leukocytosis
Shah et al. reported transient rise in peripheral white blood cell
(WBC) count following 36% of generalized seizures, 7% of complex
partial seizures, and zero cases of PNES [45]. It is believed that
excessive muscular activity secondary to catecholamine surges in
ES result in WBC margination [85,86]. This biomarker is limited by
cortisol effects and numerous other clinical situations resulting in
transient WBC elevations.
3.13. Platelet membrane serotonin transporter
Serotonin function has been implicated in numerous neuro-
psychiatric disorders, and platelets have long been investigated as
peripheral markers of CNS serotonergic activity. Cupello et al. used
a paroxetine binding system to study the density of platelet
membrane serotonin transporter (SERT) in both ES and PNES
groups [87]. The study showed a signiﬁcant decrease in platelet
SERT density in ES patients and no changes in the PNES group. The
exact mechanism for this is unclear.4. Discussion
Many biomarkers have been assessed as candidates in the
differentiation of ES from PNES. Our review indicates varying
degrees of utility in these measures, each with inherent strengths
and limitations.
Structural neuroimaging (CT, MRI) studies comparing ES and
PNES populations are few; different analyses suggest contradictory
ﬁndings and deﬁcits (some with right-sided laterality and others
with left-sided predominance); very little can be conﬁdently
extrapolated from these studies due to methodological limitations
and small sizes. Functional neuroimaging of PNES groups
repeatedly reveal impaired cortical and subcortical connectivity
at rest when compared to HC; nonetheless, these studies are
unfortunately limited by heterogeneous ﬁndings (different CNS
regions of interest), small sample sizes, no ES comparison group,
and the lack of psychiatric controls. Perez et al. [7] have recently
summarized neuroimaging studies in both PNES and functional
movement disorders, concluding that psychiatric controls with
commonly-comorbid conditions (anxiety/mood disorders) will be
needed to conﬁrm whether such functional neuroimaging ﬁndings
are speciﬁc to PNES or secondary to commonly occurring
psychiatric co-morbidities.
Histories of childhood trauma, abuse, and/or neglect are
commonly found in patients with PNES as well as in populations
with mood and anxiety disorders, undoubtedly contributing to
frequent association of PNES with these disorders. While this
demands careful psychiatric co-morbidity studies of PNES candi-
date biomarkers [88–93], fear-based anxiety disorders such as
posttraumatic stress disorder (PTSD) offer relevant psychobiologi-
cal models of PNES. A recent meta-analysis [94] of neuroimaging
studies comparing PTSD subjects with HC reveals statistically-
signiﬁcant increased activation of certain CNS structures (right
anterior insula, bilateral precuneus, left supplementary motor
area, left superior temporal gyrus, left premotor anterior cingulate
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trauma-naı¨ve HC. As many of these structures are also found to be
activated in PNES, future neuroimaging studies would require
comparison arms with ES as well as PTSD/other psychiatric
populations. Beyond these confounders, fMRI remains an imprac-
tical diagnostic tool in the differentiation of ES from PNES due to its
high cost and limited availability.
ANS studies measuring HR, HRV, and SSR collectively suggest
marked sympathetic and cardiovascular postictal changes in ES
groups as compared to PNES cohorts. These studies are
hampered by design (half are retrospective [25,26,27,29]) and
methodology (various comorbid and other confounders [29,30]);
furthermore, distal markers of increased postictal sympathetic
activity are crude measures with multiple other potential
causes, restricting their speciﬁcity. Despite these limitations,
certain indicators of ES may prove useful (e.g. prolonged return
of HR to baseline postictally [26]) as adjunct diagnostic tools
alongside other ﬁndings.
Of all the biomarkers examined in this review, PRL appears to
possess the highest and most consistent sensitivity in diagnosing
ES from PNES. This is long-known and postictal PRL levels remain a
useful and often-utilized diagnostic aid. All but two [49,50] of the
15 studies examined here conﬁrm such utility, reporting at times
sensitivity as high as 93% [47] and negative predictive value as high
as 100% [48]. According to the Therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurology
[95] PRL offers an approximate diagnostic sensitivity of 96% for all
types of ES. The Subcommittee recommends administering the PRL
test postictally within 10–20 min and promote it as a useful
adjunct in the differentiation of ES from PNES in both adults and
children.
Eight studies assessed cortisol as a biomarker in the differenti-
ation of ES from PNES; although some studies showed increased
postictal cortisol in ES groups when compared to PNES [37,39],
others showed the reverse [42] or no statistically-signiﬁcant
difference at all [53]. Of all the study groups, these investigations
showed the highest methodological heterogeneity, particularly
varying collection times and approaches. Given cortisol’s reactivity
in a number of physiological/diurnal and pathological states, its
speciﬁcity is rather low and thus should not be used as a diagnostic
aid in the diagnosis of PNES. The same can be said about related
hormones, such as ACTH and TRH.
Other protein and cellular biomarkers were examined. CK/CPK
showed the highest promise as an adjunct diagnostic tool, as
several studies [43,59–61] indicated elevated postictal CK/CPK
levels in ES groups as compared to PNES cohorts. In addition, a
delayed CK/CPK release was noted, indicating some value in later,
postictal phases of assessment. As mentioned earlier, these results
should be interpreted with caution due to multiple confounding
conditions and states that may elevate CK/CPK. However alongside
other clinical features, this marker may assist in differentiating
seizure types, particularly in the absence of other diagnostic aids or
in cases of unwitnessed events. Other protein and cellular
biomarkers either failed to demonstrate any difference or are
isolated studies requiring replication prior to conﬁrmation of their
diagnostic utility.
Our review is far from comprehensive yet offers insights into
the relative utility of various biomarkers in the clinical
evaluation or research investigation of PNES. Strengths of this
analysis include capture of an extensive array of biomarker
candidate types, a large time span, and a systematic review
methodology. Limitations include lack of review of neurophysi-
ological assessments (EEG, vEEG, SPECT), clinical approaches
(e.g. saline seizure induction, physical examination techniques,
clinical characteristics of seizures), or psychosocial/psychologi-
cal evaluations [Minnesota Multiphasic Personality Inventory(MMPI), Personality Assessment Inventory, neuropsychological
testing]. Our review was intentionally limited to biomarker
candidates with presumed diagnostic and investigational import
so as to answer questions regarding their surrogate signiﬁcance.
In addition, our analysis of studies as reported in this review is
meant to be cursory and limited in depth given journal
limitations.
It should be noted that others have reviewed diagnostic
methods utilized in differentiating ES from PNES. Cuthill and
Espie [96] examined 13 studies between the years 1984 and 2000
with a range of evaluation procedures (MMPI, saline seizure
induction, PRL, SPECT, ictal/postictal clinical characteristics, and
pre-ictal pseudosleep), but no other neuroimaging or hormonal/
cellular/protein biomarkers. The authors found varying degrees of
sensitivities and speciﬁcities for these modalities, noting that
clinical ictal characteristics showed the highest combined sensi-
tivity/speciﬁcity while postictal SPECT had the lowest combined
sensitivity/speciﬁcity. Other modalities such as pre-ictal pseudo-
sleep showed high speciﬁcity but low sensitivity while other
approaches (MMPI, patient-reported post-ictal symptoms)
showed conﬂicting evidence. The reader is referred to Cuthill
and Espie’s work for further examination.
5. Biomarkers and signiﬁcance
Our review’s focus is somewhat narrower than that taken by
Cuthill et al. in its emphasis on measurable biomarkers, yet our
scrutiny of many more studies provides a broader assessment of
candidate gauges of disease. A biomarker has been deﬁned as ‘‘a
characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention,’’ while a
surrogate is understood as ‘‘a biomarker intended to substitute for
a clinical endpoint [97].’’ Our study focused on biomarkers serving
as surrogate indicators of presence or absence of epilepsy in the
face of seizures; the ideal biomarker would reliably designate
either a seizure episode or a seizure patient as suffering from ES
versus PNES. Based on our review, postictal PRL levels may be the
most reliably elevated biomarker in ES but not in PNES, suggesting
its high utility in differentiating seizure types with or without EEG/
vEEG conﬁrmation.
Consensus groups have offered mechanisms to assess the levels
of evidence for biomarkers. Lassere et al. [98] provide a scale of
increasing validation for clinical decision-making with biomarkers
on the lower end to actual patient outcomes on the other end. In
this model, levels of evidence (Level 1 being the highest level of
evidence, Level 5 the lowest) are determined via a scoring system
assessing the target in question, studies of this target and their
designs, statistical strengths, and any penalties due to lack of
evidence or contrary evidence. Although ﬁndings from our analysis
do not translate directly to this approach, biomarker candidates
assessed in this review only approximate mid-range levels of
evidence at best (e.g. PRL alone achieves a Level 3 given reliable
ﬁndings across numerous studies, whereas other biomarkers
achieve Level 4 or 5 level of evidence). On a clinical dimension,
these biomarkers may have varying degrees of diagnostic utility,
yet none have been correlated with actual patient outcomes.
Similarly, from an investigational standpoint the biomarkers
assessed in this review remain inconclusive in elaborating the
actual pathomechanism of PNES, as none of the markers
deﬁnitively indicate presence of PNES disease and/or such markers
have not been compared with ES cohorts (as in the case with
functional neuroimaging studies).
Ultimately, biomarker candidates in PNES have failed to offer
much more than diagnostic negation (PNES is diagnosed by the
absence rather than the presence of any biological measure). Less
T. Sundararajan et al. / Seizure 35 (2016) 11–2220attention has been directed at clinical interventions with
measurable outcomes, although these have been summarized
and certain psychopharmacological (sertraline) and psychothera-
peutic (cognitive behavioral therapy, psychodynamic therapy,
group therapy) options have shown promise [2]. PNES has been
conceptualized as a truly biopsychosocial condition [4] and as such
may require complex diagnostic [99], investigational [100], and
therapeutic [101] approaches that only minimally rely on
biomarkers. Our study and its lack of a reliable, PNES-speciﬁc
biomarkers thus supports the use of clinical and psychosocial (not
neurobiological) determinants in the diagnosis and treatment of
this condition, even when vEEG-conﬁrmation is available.
6. Conclusions and future directions
This review has examined biomarker candidates that may
assist clinically in the differentiation between ES and PNES. In
addition, this review examined which indicators may beneﬁt
from future investigational analysis. As a whole, there are few if
any biomarkers with reliable utility in differentiating ES from
PNES; we thus feel there is indeed a paucity of evidence-based
support for the use of any biomarkers in the diagnosis and/or
study of PNES. PRL does offer consistent negative predictive
value; its relatively low cost and risk burden continues to
solidify its position as an attractive adjunct to clinical diagnosis.
Other markers are understudied or fail to show utility. Finally,
PNES neuroimaging studies require signiﬁcant replication in
larger samples and require comparison groups with both ES and
psychiatric comparisons. Such direct comparison with psychi-
atric populations should extend beyond neuroimaging studies to
include ANS and hormonal domains. As mentioned, a promising
psychiatric model for PNES pathophysiology is PTSD; beyond the
aforementioned neuroimaging deﬁcits shared by both PNES and
PTSD, certain other psychobiological derangements have been
demonstrated in these conditions, including sympathetic
nervous system dysregulation [102] and cortisol elevations
[103]. Dissociation has also been identiﬁed in both PNES [18,19]
and PTSD [104], suggesting one of many potential psychobio-
logical targets linking each condition. A variety of other
psychological processes (fear sensitivity, alexithymia, emotional
dysregulation, etc.) may also be examined in the context of these
comorbidities, as suggested by certain proposed psychobiologi-
cal conceptualizations [3]. Ultimately, there may not be a
unifying biomarker for PNES given its phenotypic heterogeneity,
yet the validation of certain psychobiological subtypes (disso-
ciative subtype, autonomic subtype, fear-sensitive subtype, etc.)
may prove a worthy investigational exercise for future
researchers.
In conclusion, biomarkers have offered limited beneﬁt in the
diagnostic and investigational needs surrounding PNES; speciﬁ-
cally, PRL levels offer only negative predictive value. Complex
psychosocial dimensions intrinsic to PNES will continually prevent
sole or meaningful use of cellular, hormonal, autonomic, or
neuroimaging ﬁndings in clinical care until further research is
performed. Clinically, vEEG remains the preferred modality in
differentiating ES from PNES, but in the absence of this diagnostic
modality, multidimensional biopsychosocial assessments remain
most valuable to the practicing clinician.
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